Michael R. Mcdonnell - Sep 1, 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
EVP, Chief Financial Officer
Signature
/s/ Wendell Taylor, attorney-in-fact for Michael R. McDonnell
Stock symbol
BIIB
Transactions as of
Sep 1, 2022
Transactions value $
-$485,090
Form type
4
Date filed
9/6/2022, 07:31 PM
Previous filing
May 26, 2022
Next filing
Feb 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +2.68K +60.58% $0.00 7.11K Sep 1, 2022 Direct F1
transaction BIIB Common Stock Tax liability -$274K -1.37K -19.3% $199.79 5.74K Sep 1, 2022 Direct
transaction BIIB Common Stock Options Exercise $0 +2.06K +35.98% $0.00 7.8K Sep 1, 2022 Direct F2
transaction BIIB Common Stock Tax liability -$211K -1.06K -13.54% $199.79 6.75K Sep 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -2.68K -50% $0.00 2.68K Sep 1, 2022 Common Stock 2.68K $0.00 Direct F1
transaction BIIB Restricted Stock Unit Options Exercise $0 -2.06K -19.24% $0.00 8.66K Sep 1, 2022 Common Stock 2.06K $0.00 Direct F2
transaction BIIB Restricted Stock Unit Other $0 -3.3K -38.07% $0.00 5.37K Sep 1, 2022 Common Stock 3.3K $0.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 09/01/2020.
F2 The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F3 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.